Demand for tinniwell increases monthly by about 10%
Egnach, February 6, 2024 – Since August 2023, the demand for the tinnitus therapy device tinniwell has been increasing by an average of 10% per month. The cause is the COVID wave that began in the summer of 2023. The flattening of the waves described by experts at the beginning of the pandemic is in no way observable in terms of tinnitus. On the contrary, the number of patients with the long-Covid symptom tinnitus is skyrocketing. This increasingly affects more and more individuals who have never dealt with tinnitus before. In previous COVID waves, mostly only patients who already suffered from tinnitus before the infection were affected.
++ About Resaphene Suisse AG
Resaphene Suisse AG, based in Egnach, Switzerland, is a medical technology company founded in 2015 and has been marketing a tinnitus therapy device under the name tinniwell since 2016.
++ Contact for inquiries:
Resaphene Suisse AG
Ms. Anke Rauterkus (Chief Executive Officer)
Bahnhofplatz 5
9322 Egnach
Switzerland
T. +41 714500668